ArticleCancer discovery2023

CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma.

Sarah M Larson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.